# vVARDIS

> Swiss dental-medtech company selling clinician-applied Curodont peptide products for early-stage tooth decay; NYSE: VVVV since November 13, 2026.

## Why it is interesting

vVARDIS priced 9,722,223 Class A shares at $18 on Nov 13, 2026 (~$175M gross IPO) after an indicated $21–$24 range. Its Curodont product is already distributed to US dentists through Henry Schein. Crucial distinction: NYSE trading began Nov 13, while IPO legal settlement was scheduled for about Nov 16 and unconfirmed at research time. OrbiMed's two 2025 financings totaled $85M but their debt/equity composition should not be invented.

## Profile

- **Latest funding:** Not publicly disclosed
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** public
- **Status:** public
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-16

## Key facts

- Issuer announcement Nov 13 2026: 9,722,223 IPO shares × $18 = $175,000,014 gross before fees; additional 1,458,333 underwriter option shares not included. NYSE ticker VVVV. Legal close expected around Nov 16, subject to conditions.
- IPO price was below the $21–$24 preliminary range; an IPO price is not a transaction valuation and does not itself prove eventual legal proceeds paid.
- 2025 issuer disclosures: OrbiMed initial $35M financing closed February; additional $50M closed July, $85M combined. Instruments and refinancing component must not be assumed to be entirely new equity.
- Official Curodont Repair Fluoride Plus professional instructions restrict use to trained in-office providers for early caries; advanced cavitated lesions may still require conventional restoration.
- FY2025 issuer filing figures: ~$30.2M revenue versus ~$56.4M net loss; Henry Schein accounted for ~72% of sales in 2025 and ~90% in H1 2026, exposing customer concentration. F-1 disclosures, not unaudited marketing claims.
- Company announced Apollo-managed funds' minority investment in April 2026; precise invested amount and transaction valuation undisclosed despite issuer's 'unicorn' description.

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 16, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/vvardis
